Tickernomics

10y

Historical Returns*:

SPY

27.80%

BPMC

0.30%

SPY

32.66%

-15.23%

BPMC

SPY

108.59%

BPMC

12.74%

SPY

302.52%

BPMC

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

5733.45

5084.20

0.27

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-44.77

13.20

18.31

-4.42

0.00

-24.96

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-38.21

98.49

-41.51

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

6.528

-66.33

-21.97

0.60

Other Earnings and Cash Flow Stats:

Blueprint Medicines Corp ( BPMC ) Net Income TTM ($MM) is -128.05

Blueprint Medicines Corp ( BPMC ) Operating Income TTM ($MM) is -275.95

Blueprint Medicines Corp ( BPMC ) Owners' Earnings Annual ($MM) is 0.00

Blueprint Medicines Corp ( BPMC ) Current Price to Owners' Earnings ratio is 0.00

Blueprint Medicines Corp ( BPMC ) EBITDA TTM ($MM) is -262.13

Blueprint Medicines Corp ( BPMC ) EBITDA Margin is -41.51%

Capital Allocation:

Blueprint Medicines Corp ( BPMC ) has paid 0.00 dividends per share and bought back -2.693 million shares in the past 12 months

Blueprint Medicines Corp ( BPMC ) has reduced its debt by 260.721 million USD in the last 12 months

Capital Structure:

Blueprint Medicines Corp ( BPMC ) Interest-bearing Debt ($MM) as of last quarter is 84

Blueprint Medicines Corp ( BPMC ) Annual Working Capital Investments ($MM) are -79

Blueprint Medicines Corp ( BPMC ) Book Value ($MM) as of last quarter is 313

Blueprint Medicines Corp ( BPMC ) Debt/Capital as of last quarter is 27%

Other Balance Sheet Stats:

Blueprint Medicines Corp ( BPMC ) has 89 million in cash on hand as of last quarter

Blueprint Medicines Corp ( BPMC ) has 257 million of liabilities due within 12 months, and long term debt 386 as of last quarter

Blueprint Medicines Corp ( BPMC ) has 63 common shares outstanding as of last quarter

Blueprint Medicines Corp ( BPMC ) has 0 million USD of preferred stock value

Academic Scores:

Blueprint Medicines Corp ( BPMC ) Altman Z-Score is 1.53 as of last quarter

Blueprint Medicines Corp ( BPMC ) Piotroski Score is 3.00 as of last quarter

Corporate Governance:

Blueprint Medicines Corp ( BPMC ) largest shareholder is owning shares at 0.00 ($MM) value

Albers Jeffrey W.(an insider) Sold 2100 shares of Blueprint Medicines Corp ( BPMC ) for the amount of $193116.00 on 2024-12-19

0.92% of Blueprint Medicines Corp ( BPMC ) is held by insiders, and 106.22% is held by institutions

Blueprint Medicines Corp ( BPMC ) went public on 2015-04-30

About Blueprint Medicines Corp ( BPMC ) :

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.